Home > News > Kereos' Collaborators Present on Targeted Therapies
November 15th, 2005
Kereos' Collaborators Present on Targeted Therapies
Abstract:
Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease, announced today that the company's collaborators at Washington University School of Medicine will be presenting preclinical data on two therapeutic candidates at the American Heart Association (AHA) Scientific Sessions this week. These agents are the first cardiovascular-targeted therapeutics in Kereos' pipeline of ligand-targeted emulsions, and represent two of the first applications of nanotechnology to treating cardiovascular disease.
Source:
prnewswire
Bookmark:
| Related News Press |
Possible Futures
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||